As part of its commitment to reducing the inappropriate use of antipsychotics, in February, CMS strengthened the Five Star Rating System to include the use of antipsychotics for both long and short-stay residents except for those with schizophrenia, Huntington’s disease, or Tourette syndrome. They anticipate a 30 percent reduction in antipsychotic use in residents with dementia as a result of this action. Note that no exception was made for the management of terminal delirium.
Consult Enclara Pharmacia pharmacists for guidance in antipsychotic discontinuation or recommendations for alternative therapies. Enclara Pharmacia is also providing a webinar on this topic on April 23rd. Click here for additional information about the webinar.
